Abstract 243P
Background
Cervical cancer ranks as 2nd leading cause of female cancer in Indonesia. Early detection of cervical cancer is crucial for early treatment and reduce risk of mortality. Despite the evidence of cervical cancer screening is associated with decrease mortality from this disease, the uptake for cervical cancer screening among Indonesian women in suburban area of Banten remains low. The aim of this study is to discover factors that associate with uptake of cervical cancer screening and report on cervical cancer prevalence among women in suburban area of Banten.
Methods
This is a cross sectional study that took the mass screening in 3 different primary health care in Banten, Indonesia. We included female who had never done screening for cervical cancer and aged 21-65 years old. Cervical sample were collected for Papanicolaou smear and evaluated by pathologist.
Results
Pap smears of 309 females were taken. It was observed that 74,11% (n = 229) of females were negative for cervical intraepithelial lesion or malignancy. Our data showed that 13,5% (n = 42) had bacterial vaginosis, 6.14% (n = 19) had candida infection. Respectively ,for low grade squamous intraepithelial lesion (LSIL) and high grade intraepithelial lesion were 2,26%( n = 7) and 1,61 % (n = 5). Cervical cancer was positive for 0.97% (n = 3) and 1.29% (n = 4) had atropic vaginitis. The significant predictor for uptake of cervical cancer screening were being married, older age, and knowing a person with cervical cancer with p value 0.004, 0,037 and <0,001. The only significant factor that contribute to reduce uptake of screening is did not know where to go for screening and the price of screening with p value of 0,024 and 0.017.
Conclusions
Mass screening and public education is a crucial step to reduce morbidity and mortality of cervical cancer. Poor hygiene environment in suburban region increase incidence of infection that lead to causative factors for cervical cancer. Intensification of primary health care for cancer screening is needed to reduce the national burden of cervical cancer in Indonesia.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Faculty of Medicine, Pelita Harapan University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
259P - The BOT patients fail to benefit from surgical staging procedures in prognosis and fertility outcomes: A retrospective analysis
Presenter: Li Na
Session: Poster display session
Resources:
Abstract
260P - Malignant ovarian germ cell tumours (MOGCT): Treatment results of 149 pts
Presenter: Dzhennet Chekini
Session: Poster display session
Resources:
Abstract
261P - Ovarian germ cell tumours - challenges and outcomes from a tertiary care centre in South India
Presenter: Vishnu Sreedath
Session: Poster display session
Resources:
Abstract
262P - Gestational trophoblastic tumours: Experience of the medical oncology department Hassan II University Hospital-Morocco about 29 cases
Presenter: Karima Oualla
Session: Poster display session
Resources:
Abstract
263TiP - ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
264TiP - ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
265TiP - KEYNOTE-826: A phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
271P - Comparison between CHOP like regimens and DAEPOCH with or without Rituximab in adult high grade B cell lymphoma NOS; A retrospective study from a tertiary cancer hospital in South India
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
272P - Melatonin increases the chemosensitivity of diffuse large Bell lymphoma cells to Epirubicin by inhibiting P-glycoprotein expression via the NF-κB pathway
Presenter: Xiuhua Sun
Session: Poster display session
Resources:
Abstract
273P - MALT1- A20 and NF-κB expression pattern in patients with non-Hodgkin lymphomas
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract